UNSPSC 51151921: Phenprobamate

This classification denotes a carbamate with the molecular formula C10H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UJZ473TPS0, chemically known as 1-propanol, 3-phenyl-, carbamate but generally known as phenprobamate, which bears US NIH Compound Identifier 4770. European Medicines Agency schedules Phenprobamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09780MIG. World Health Organization schedules phenprobamate in its Anatomical Therapeutic Chemical (ATC) Classification.

UNSPSC 51151921 Phenprobamate, a Commodity-tier code, is fundamentally misaligned with the actual work being solicited under it in state and local procurement. The code nominally describes phenprobamate, a muscle relaxant pharmaceutical, but recent opportunities tagged to this code cover naloxone procurement and pharmacy benefit program strategy — neither of which relates to phenprobamate supply. The issuing bodies are county health departments and state health agencies (Seminole County, Florida and the Texas Health and Human Services Commission), which are typical customers for pharmaceutical and pharmacy-related procurements, but the mismatch between the code's technical scope and the goods and services being purchased signals either a cataloging error in the source system or a deliberate use of an unrelated code to classify these opportunities.

The two recent opportunities show minimal thematic coherence under this code. Seminole County posted an IFB on June 30, 2026 (response deadline July 26, 2023 — an apparent date error in the source) for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries required to Sanford, Florida and a fixed-fee contract structure. The Texas Health and Human Services Commission issued an RFI posted April 3, 2026 (response deadline the same day) to gather market intelligence on direct-to-manufacturer prescription programs and vendor capacity to bypass traditional pharmacy benefit managers. Neither opportunity involves phenprobamate procurement, and the naloxone and pharmacy strategy solicitations do not share a common vendor or operational scope. The code shows little relevant recent activity aligned with its nominal scope; firms evaluating this code should cross-reference naloxone or pharmacy benefit management classifications to capture the actual work being solicited.